Lpath to Present at ROTH Capital Partners 25th Annual Growth Stock Conference
on March 19, 2013
SAN DIEGO, CA -- (Marketwire) -- 03/12/13 -- Lpath, Inc. (NASDAQ:
LPTN), the industry leader in bioactive lipid-targeted therapeutics,
has been invited to present at the ROTH Capital Partners 25th Annual
Growth Stock Conference being held on March 17-20, 2013, at The Ritz
Carlton in Dana Point, Calif.
Lpath President and CEO Scott Pancoast is scheduled to present on
Tuesday, March 19, 2013 at 1:00 p.m. Pacific time, with one-on-one
meetings held throughout the day. He will discuss the company's
pathway to regulatory approval and commercialization of its novel
lipidomics-based therapeutics, as well as its ability to attract
support from financial and strategic partners such as Pfizer, J&J,
Biogen Idec, and Merck-Serono, as well as the NIH and the Department
The presentation will be webcast live at
http://www.wsw.com/webcast/roth27/lptn/, which will be available for
replay in the investor relations section at www.lpath.com.
For more information about the conference or to schedule a one-on-one
meeting with Lpath management, please contact your ROTH
representative at 1-800-933-6830 or via e-mail at
About ROTH Capital Partners
ROTH Capital Partners, LLC (ROTH), is a
relationship-driven investment bank focused on serving emerging
growth companies and their investors. As a full-service investment
bank, ROTH provides capital raising, M&A advisory, analytical
research, trading, market-making services and corporate access.
Headquartered in Newport Beach, CA, ROTH is privately-held and
employee owned, and maintains offices throughout the U.S. and Hong
Kong. For more information on ROTH, please visit www.roth.com.
San Diego-based Lpath, Inc., a therapeutic antibody
company, is the category leader in lipid-targeted therapeutics. The
company's ImmuneY2(TM) drug-discovery engine has the unique ability
to generate monoclonal antibodies that bind to and inhibit bioactive
lipids that contribute to disease. The company is developing three
drug candidates: iSONEP(TM) is in a Phase 2 trial for wet AMD;
ASONEP(TM) is in a Phase 2 trial in Renal Cell Carcinoma patients;
and Lpathomab is a preclinical drug candidate that holds promise in
pain, neurotrauma, and other diseases.
Scott R. Pancoast
President & CEO
Tel: (858) 926-3200
Lpath Investor Relations
Liolios Group, Inc.
Tel: (949) 574-3860
Ron Both: email@example.com
Geoffrey Plank: firstname.lastname@example.org
Press spacebar to pause and continue. Press esc to stop.